Welcome to the OMA Blog

Our society can be hostile toward people with obesity who commonly face judgment, prejudice, and unfair treatment in their daily lives. This problem extends to the healthcare setting, where patients can face weight bias and stigma from physicians, nurses, psychologists, dietitians, medical students, and even healthcare professionals who specialize in obesity.

Insulin is a commonly used medication to treat patients with both type 1 and type 2 diabetes. Weight gain is a commonly seen side effect. Patients may have questions about insulin and potential weight gain out of concern for their appearance or their health (or both).

Does your health care provider talk to you about your Body Mass Index (BMI) and do you know what it really means? Widely criticized as…

Learn about the side effects of weight loss drugs, from digestive issues to long-term impacts. Get the facts before starting your regimen.

Today, there's renewed optimism due to the emergence of GLP1-based drug therapies like Wegovy (semaglutide) and Zepbound (tirzepatide), which demonstrate remarkable effectiveness for weight and health. Unfortunately, many of the available alternatives, like compounded versions of semaglutide and tirzepatide, are not what they are advertised to be. These companies stated that they do not sell the active ingredient to compounding pharmacies, and substances made or distributed by compounding pharmacies or other healthcare practitioners that claim to be semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) have not been reviewed by the FDA for safety, quality, or efficacy. For more information, see the following details: Compounded peptides: An Obesity Medicine Association Position Statement - ScienceDirect | Obesity Medicine Association Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA Compounding and the FDA: Questions and Answers | FDA Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide) | Eli Lilly and Company Responsible Use Letter | Novo Nordisk Things You Should Know About Compounded Anti-Obesity (AOM) Medications | Obesity Medicine Association

In 2013, the AMA declared that obesity is a disease, a controversial claim that has sparked debate. OMA explains why we believe that obesity is a disease.

As the Thanksgiving dinner settled into a cozy ambiance, the delightful aroma of roasted turkey filled the air. Among the gathering of family and friends, the lively conversations took an unexpected turn when a family member turned to dinner conversation for an opportunity to share knowledge about sleep and obesity.

The recent results of the SELECT Study published in the New England Journal of Medicine provide invaluable insights into the complex disease of obesity. The report has prompted several of the country’s leading obesity expert organizations, the Obesity Action Coalition (OAC), the Obesity Medicine Association (OMA), The Obesity Society (TOS), the American Society for Metabolic & Bariatric Surgery (ASMBS), and the STOP Obesity Alliance (STOP), to join together in issuing the following statement:

Is obesity genetic? Do our genes determine if we'll have a healthy body weight or not? Explore the role of genetics in the obesity epidemic.